• Mary Ann B. Case, RN, MSN, OCN

    Mary Ann B. Case, RN, MSN, OCN
    Clinical Nurse Specialist

    Phone: 617-632-2224
    Email: mary_case@dfci.harvard.edu



    Patient navigation, Cancer survivorship

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215


    I have been a nurse at Dana-Farber since 1979.  I have more than 30 years of experience caring for oncology patients, and 13 years specializing in head and neck oncology. I am a member of the Oncology Nursing Society and am active in our local chapter serving on the program committee. As a Magnet designated center for nursing excellence there are ample opportunities to participate in nursing shared governance at DFCI. As a Clinical Nurse Specialist I represent my department on the Nursing Council, the Program Nurse Council and various other committees.  I also participate in orientation of new Nursing and Patient Care Services employees and support their continued clinical practice.  


    Education and Training
    State University of New York, College at Plattsburgh, BSN, 1977
    Framingham State College, MSN, 2010

    Getting Research and Nurses Together Workshop Series: Brigham and Women’s Hospital Center for Excellence in Nursing Practice, 2003-2004
    Palliative Care Resource Nurse Task Force, 1999-2001
    Clinical Elective in Therapeutic Touch, 1999
    Oncology Nursing Certification (OCN), 1996-present


    • Education Scholarship, Boston Oncology Nursing Society , 2008
    • Nursing Research and Patient Care Service Clinical Scholar Award, Dana-Farber Cancer Institute, 2005

    Select Publications

    • Tishler RB, Norris CM, Colevas AD, Lamb C, Karp D, Busse PM, Nixon A,  Frankenthaler R,  Lake-Wilcutt B,  Costello R, Case M, Posner M. (2002). A Phase I/II trial of concurrent docetaxel and radiation following induction chemotherapy in poor prognosis squamous cell cancer of the head and neck. Cancer, 95, 1472-1481
    • Haddad RI, Tishler RB, Norris CM, Busse PM,  Sullivan CA, Goguen LA, Lake-Willcutt L, Case MA, Costello R,  Posner M. (2003). Docetaxel, cisplatin and 5-fluorouracil based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: The Dana-Farber Cancer Institute experience. Cancer, 97(2), 412-418.
    • Haddad RI, Tishler RB, Norris CM, Mahadevan A, Busse PM, Wirth L, Goguen LA, Sullivan CA, Costello R, Case M,  Posner MR. (2003). Taxotere, cisplatinum, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined modality treatment. The Oncologist, 8, 35-44.
    • McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Posner MR, Van den Abbeele AD. (2004). Positron emission tomography with 18-F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head and Neck, 26, 890-896.
    • Tishler RB, Posner MR, Norris CM, Mahadevan A, Sullivan C, Goguen L, Wirth L, Costello R, Case M, Stowell S, Sammartino D, Busse P, Haddad RI. (2006). Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.  International Journal of Radiation Oncology, Biology, and Physiology, 65(4), 1036-1044.
    • Case MAB. (2011). Oncology nurse navigator: Ensuring safe passage. Clinical Journal of Oncology Nursing, 15(1), 33-40.